The Wire › Story

RANK 5/10 · SIGNIFICANTDISEASE

WHO experts recommend testing two vaccines built for the Bundibugyo Ebola…

WHO experts recommend testing two vaccines built for the Bundibugyo Ebola strain in the trial running in Congo

Confirmed by 1 independent source · First seen Nov 7, 2026, 2:20 PM EST · Updated Nov 12, 2026, 3:07 PM EST

SharePost on X
Bottom lineRisk · Medium

There is no approved vaccine for this strain, which has killed more than 5,000 people in Congo since May.

BLACKOUT.NETWORK desk brief, written Nov 12, 5:58 PM EST from the sources listed below.

5of 10 · SignificantDISEASE AND OUTBREAKS1reports logged1independent sources1official sources5 daystracked so far
Graphic: BLACKOUT.NETWORK, built from the 1 report on this page. No rights-cleared photo of this event was available.

01What happened

Expert groups convened by WHO recommended adding two vaccine candidates to the Tumaini clinical trial in Congo, WHO said on Nov. 4: Oxford and the Serum Institute of India's ChAdOx1, and Moderna's mRNA-1469. WHO says it is the first time vaccines designed specifically for Bundibugyo virus will be tested during an outbreak of it. At the time, the US CDC counted 10,699 cases and 5,202 deaths, CIDRAP reported.

02Why it matters

The candidates join the trial after the approvals WHO describes. Testing during an outbreak is the fastest way to learn whether a vaccine works, but results will take time. Meanwhile MSF is pushing for wider use of the existing Ervebo vaccine, which targets a different strain.

  • It is one of 2 related disease and outbreaks stories on our board in the past 7 days.

Related: "With the number of confirmed cases now surpassing 11,000, the outbreak — declared in…

03Why we ranked it this way

  • Our read: WHO's own announcement plus CIDRAP and European CDC data; a 5, Significant, fits a step forward in the response.
  • 5/10, Significant. That is our level for stories whose reach is regional / national.
  • Confirmation: Confirmed by official sources (CIDRAP News). This rank needs: official source, or 2+ independent sources.
Signal snapshot

Rank 5 of 10 · Significant

Rank
5/10
Significant
Independent sources
1
Official sources
1
Reports logged
1

Built from the reports BLACKOUT.NETWORK logged for this story. Rank rules: How we score.

04Risk factor

Our analysts rate this medium: The outbreak is serious, but this news is a step forward and poses no new risk.

05If it’s true, if it’s overblown

If it’s true

If the trial vaccines work, they could be used to protect health workers and contacts in this and future outbreaks.

If it’s overblown

If they fail or are delayed, the response relies on tracing, isolation and possibly wider use of Ervebo. Our confidence in the reporting is high: WHO's official announcement, CIDRAP and the European CDC.

06What you should do

  1. No action is needed.

07Sources

  1. who.int
  2. cidrap.umn.edu
  3. ecdc.europa.eu

Get the free 7 AM / 7 PM brief

How confident are we?

1 independent source, including official sources: CIDRAP News. Ranks come from published rules; see How we score.

Timeline and sources

Follow this story

Get an UPDATE in your BLACKOUT.NETWORK brief only when this story develops. Subscribers: tap “Follow this story” under the item in any brief. Not subscribed yet? Get the free morning/evening brief.

Follow

Ranked, sourced alerts as they happen.

← Back to The Wire · How we score · Videos · Newsletter